EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, VIVUS's enterprise value is €2.66 Mil.
VIVUS's Revenue for the trailing twelve months (TTM) ended in Mar. 2020 was €65.89 Mil. Therefore, VIVUS's EV-to-Revenue for today is 0.04.
The historical rank and industry rank for VIVUS's EV-to-Revenue or its related term are showing as below:
STU:VIU1's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.82 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-05-31), VIVUS's stock price is €0.06.
VIVUS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2020 was €6.19. Therefore, VIVUS's PS Ratio for today is 0.01.
VIVUS EV-to-Revenue Historical Data
The historical data trend for VIVUS's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, VIVUS's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VIVUS's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VIVUS's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where VIVUS's EV-to-Revenue falls into.
VIVUS's current Enterprise Value is €2.66 Mil.
VIVUS's Revenue for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was €65.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VIVUS's share price for today is €0.06.
VIVUS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.19.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VIVUS EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of VIVUS's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:VIU1 has been successfully added to your 